Answers are grounded in this paper and cite their sources.
This review regards various attitudes to the rational design of prodrugs derived of nucleoside and nucleotide analogues with pronounced biological (antiviral, anticancer) activity. Particular attention is focused on the recent development of prodrugs of approved therapeutic agents with the above structural association.
No takes yet. Share an insight, caveat, or question.
Alexander et al. (1994) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: